Passa al contenuto
Merck
Tutte le immagini(2)

Documenti

SML0700

Sigma-Aldrich

FTY720

≥98% (HPLC), powder, immunomodulating drug

Sinonimo/i:

2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol hydrochloride, Fingolimod hydrochloride

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(2)

About This Item

Formula empirica (notazione di Hill):
C19H33NO2 · HCl
Numero CAS:
162359-56-0
Peso molecolare:
343.93
Codice UNSPSC:
12352211
NACRES:
NA.77

product name

FTY720, ≥98% (HPLC)

Saggio

≥98% (HPLC)

Forma fisica

powder

Condizioni di stoccaggio

desiccated

Colore

white to beige

Solubilità

water: 10 mg/mL, clear

Temperatura di conservazione

−20°C

InChI

1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H
SWZTYAVBMYWFGS-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

FTY720 has been used as an immunomodulator and is used to investigate its effect on in vitro gastrulation model of P19C5 stem cells. It is also used to determine its efficacy in prolonging the survival corneal transplantation. FTY720 has been used to study its effect on the proliferation and differentiation of cultured embryonic hippocampal neural stem cells (NSCs) using the 5-bromo-2-deoxyuridine incorporation assay, the neurosphere formation assay and western blot analysis.

Azioni biochim/fisiol

FTY720 is an immunomodulating drug and sphingosine 1-phosphate (S1P) receptor modulator. Phosphorylation of FTY270 by sphingosine kinase causes S1P1R internalization, which sequesters lymphocytes in lymph nodes, preventing them from taking part in an autoimmune response. Clinically, it has been approved for the treatment of multiple sclerosis (MS). It has also been shown to block and reverse paclitaxel-induced chemotherapy induced peripheral neuropathy (CIPN) through S1PR inhibition as well as inhibit the activity of histone deacetylases in the hippocampus of mouse brains, thereby modulating memory.

Pittogrammi

Health hazard
GHS08

Avvertenze

Warning

Indicazioni di pericolo

H373

Consigli di prudenza

P260 - P314 - P501

Classi di pericolo

STOT RE 2

Organi bersaglio

Immune system

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Veronique E Miron et al.
Journal of the neurological sciences, 274(1-2), 13-17 (2008-08-06)
FTY720, also known as fingolimod, is an orally administered sphingosine-1-phosphate (S1P) analogue that is under investigation as a therapy for both relapsing-remitting (RR) and progressive forms of multiple sclerosis (MS). The demonstrated beneficial effect of FTY720 on disease activity in
Mohammad G Mohammad et al.
The Journal of clinical investigation, 124(3), 1228-1241 (2014-02-27)
In the CNS, no pathway dedicated to immune surveillance has been characterized for preventing the anti-CNS immune responses that develop in autoimmune neuroinflammatory disease. Here, we identified a pathway for immune cells to traffic from the brain that is associated
Darren Ruane et al.
The Journal of experimental medicine, 210(9), 1871-1888 (2013-08-21)
Developing efficacious vaccines against enteric diseases is a global challenge that requires a better understanding of cellular recruitment dynamics at the mucosal surfaces. The current paradigm of T cell homing to the gastrointestinal (GI) tract involves the induction of α4β7
Douglas Kazutoshi Sato et al.
Journal of neuroimmunology, 268(1-2), 95-98 (2014-02-11)
Fingolimod has demonstrated efficacy in patients with multiple sclerosis (MS), and patients become gradually lymphopenic after a few days of treatment, with selective reductions in CD4+ subsets. We observed an increase in the frequencies of circulating regulatory T cells after
Goeril Karlsson et al.
Neurology, 82(8), 674-680 (2014-01-28)
To report outcomes of pregnancies that occurred during the fingolimod clinical development program. Pregnancy outcomes from phase II, phase III, and phase IV clinical studies (with optional extensions) were reported by clinical trial investigators. Fingolimod exposure in utero was defined
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.